362 related articles for article (PubMed ID: 29747274)
1. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].
Yan YJ; Fan YL; Yu SW; Ye Q
Zhonghua Jie He He Hu Xi Za Zhi; 2018 May; 41(5):327-332. PubMed ID: 29747274
[No Abstract] [Full Text] [Related]
2. The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis.
Ogawa K; Miyamoto A; Hanada S; Takahashi Y; Murase K; Mochizuki S; Uruga H; Takaya H; Morokawa N; Kishi K
Intern Med; 2018 Oct; 57(19):2813-2818. PubMed ID: 29780123
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
4. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
5. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
Wijsenbeek MS; Grutters JC; Wuyts WA
Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
14. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
15. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
16. Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
Fang C; Huang H; Guo J; Ferianc M; Xu Z
PLoS One; 2020; 15(1):e0228390. PubMed ID: 31999801
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
Shi H; Yin D; Bonella F; Kreuter M; Oltmanns U; Li X; Peng S; Wei L
BMC Pulm Med; 2020 May; 20(1):128. PubMed ID: 32380989
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
